Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 4 2Phase NA 1Phase 2/3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Hot Flashes 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Venlafaxine Hydrochloride × Clear all
NCT06106529 2025-02-04

REDFLASH

Reinier de Graaf Groep

Phase 3 Recruiting
260 enrolled
Breast

Breast Neoplasms

NCT00354432 2021-09-28

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Wake Forest University Health Sciences

Phase 3 Terminated
120 enrolled 11 charts
Genitourinary

Prostatic Neoplasms, Hot Flashes

NCT01011751 2015-07-30

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Takeda

Phase 3 Completed
311 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡